INTRODUCTION
============

*Helicobacter pylori* (*H. pylori*) is strongly associated with gastric cancer (GC) through epidemiologic and clinical studies, and it has been classified as a class I carcinogen by International Agency for Research on Cancer.[@b1-jcp-19-056] However, the etiology of GC is not limited to *H. pylori* infection. Dietary factors such as salt and nitrates contribute to the development of GC, and Epstein-Barr virus (EBV) is also responsible for approximately 5% of GC cases.[@b2-jcp-19-056] Although the definition of *H. pylori* infection-negative gastric cancer (HPIN-GC) has not been established well, the prevalence of HPIN-GC is considered low, especially in Korea and Japan.[@b3-jcp-19-056]--[@b7-jcp-19-056] The reported prevalence in both countries ranged from 0.66% to 10.6%.[@b4-jcp-19-056],[@b6-jcp-19-056],[@b7-jcp-19-056] Our group reported that 5.4% cases of GC were negative for *H. pylori* infection.[@b7-jcp-19-056]

The prognosis of HPIN-GC has been rarely investigated in the literature.[@b3-jcp-19-056],[@b5-jcp-19-056],[@b8-jcp-19-056] In two studies conducted in Western countries,[@b3-jcp-19-056],[@b5-jcp-19-056] the positivity of *H. pylori* infection in GC patients was 24.7% and 14.0%, respectively. The survivals in *H. pylori*-infection positive gastric cancer (HPIP-GC) patients were better than those in HPIN-GC, and the *H. pylori* infection status was reported to be an prognostic factor, independently of other well-known prognostic factors.[@b3-jcp-19-056],[@b5-jcp-19-056] In term of the diagnostic methods, the *H. pylori* status in GC patients was assessed by bacterial culture, histological analysis, serology, and/or PCR method. However, the diagnostic criteria were not as strict as in the recent research on the prevalence of HPIN-GC, and the status of *H. pylori* infection in the two studies was not properly evaluated. In the recent prevalence studies, including our report, strict definitions of *H. pylori* infection were employed, and precise diagnosis of HPIN-GC was tried with a combination of various diagnostic methods.[@b6-jcp-19-056],[@b7-jcp-19-056]

With regard to the carcinogenesis of GC, genetic and epigenetic changes in oncogenes and tumor suppressor genes, cell cycle regulators, and DNA repair genes have been reported.[@b9-jcp-19-056] The microsatellite instability (MSI) is defined as length changes of microsatellites, which are repeating sequences of 1--6 base pairs of DNA. The MSI is caused by an impairment of DNA mismatch repair system.[@b9-jcp-19-056] The p53 tumor suppressor gene is the most commonly mutated gene in various human cancers, and alteration or inactivation of p53 allows a cell with damaged DNA to escape from normal growth, resulting in cancer development.[@b9-jcp-19-056],[@b10-jcp-19-056] The mutated p53 proteins accumulate with a prolonged half-life in amounts and can be detected by immunohistochemical methods.[@b10-jcp-19-056] In GC patients, the clinicopathologic characteristics and prognostic roles of MSI and p53 expression have been reported in several studies.[@b11-jcp-19-056]--[@b15-jcp-19-056] However, considering of the majority of HPIP-GC in GC patients, the results of the previous reports could represent the role of MSI and p53 expression in HPIP-GC. To our knowledge, there is no study evaluating the molecular prognostic markers such as MSI and p53 expression, confined to HPIN-GC.

The aim of the present study was to compare the clinicopathological and molecular features of HPIN-GC with those of HPIP-GC, applying a strict definition of *H. pylori* status, and to analyze the prognosis of GC patients according to the *H. pylori* status. In addition, the usefulness of the molecular prognostic markers established in HPIP-GC was re-evaluated in HPIN-GC.

MATERIALS AND METHODS
=====================

1.. Patients
------------

Between June 2003 and October 2012, patients diagnosed as gastric cancer by endoscopic biopsy were prospectively enrolled at Seoul National University Bundang Hospital, South Korea. Patients who had not received endoscopic resection or surgery, or who had been lost from follow-up were excluded from the present study. Patients with complete disappearance of GC after endoscopic biopsy and incomplete medical records were also excluded. All patients were ethnically Koreans and provided informed consent. The study protocol was approved by the Ethics Committee at Seoul National University Bundang Hospital.

2.. Initial Determination of *H. pylori* Infection Status
---------------------------------------------------------

To determine the current status of *H. pylori* infection, three biopsy-based tests (histology, rapid urease test, and culture) were employed. The protocols for the three tests were previously described in detail.[@b7-jcp-19-056] To identify previous *H. pylori* infection, the sero-positivity and eradication history were investigated. Sero-positivity was assessed by enzyme-linked immunosorbent assay (ELISA) for anti-*H. pylori* antibody in each patient's serum (Genedia *H. pylori* ELISA; Green Cross Medical Science Corp, Eumsung, South Korea). In addition, eradication history was evaluated in each patient by a questionnaire.

3.. Evaluation of Gastric Atrophy by Serum Pepsinogen Test and Histologic Findings
----------------------------------------------------------------------------------

In fasting serum collected from each patient, the concentrations of pepsinogen (PG) I and II were measured using a Latex-enhanced Turbidimetric Immunoassay (Shima Laboratories, Tokyo, Japan). Based on the results, patients were categorized as having no, mild to moderate, or severe gastric atrophy as previously described[@b4-jcp-19-056],[@b7-jcp-19-056],[@b16-jcp-19-056]; no atrophy, PG I \>70 and PG I/II ratio \>3.0; severe atrophy, PG I≤30 and PG I/II≤2.0; mild and moderate atrophy, 30\< PG I≤70 and 2.0\< PG I/II≤3.0. The status of gastric atrophy was also evaluated by histology, using four biopsy specimens obtained from each patient (one each from greater and lesser curvatures of antrum and body). The gastric mucosa was categorized as having no atrophy, non-metaplastic atrophy, metaplastic atrophy, or non-applicable as recommended by international group of pathologists.[@b17-jcp-19-056]

4.. EBV In Situ Hybridization
-----------------------------

Sections were digested with proteinase K and were hybridized for 2 h at 37°C with a fluorescein-conjugated EBV oligonucleotide probe for EBV-encoded small RNAs (EBERs; Novocastra, Newcastle upon Tyne, United Kingdom). Hybridization products were detected using an alkaline phosphatase-conjugated antibody to FITC \[affinity-isolated rabbit F(ab')\]. 5-bromo-4-chloro-3-indolylphosphate-nitroblue tetrazolium was used as an enzyme substrate to demonstrate alkaline phosphatase activity, and it were counterstained with Mayer's hematoxylin. Positive staining was observed under light microscopy as black granules at the site of hybridization. Only those cases with signals within tumor cell nuclei were considered to be positive.[@b18-jcp-19-056]

5.. p53 Immunohistochemistry
----------------------------

Sections 4*μ*m thick were cut from each tissue array block and then deparaffinized and dehydrated. Immunohistochemical staining was performed using an automatic immunostainer (BenchMark^®^ XT, Ventana Medical Systems Inc., Tucson, AZ) according to the manufacturer's instructions. The primary antibody used was mouse monoclonal antibody for p53 (DO7, Dako, Carpinteria, Calif., USA). An antigen retrieval process was performed using microwave. Immunostaining 10% or more nuclear staining of tumor cells was considered positive.[@b19-jcp-19-056]

6.. MSI Testing
---------------

Tumor DNA was extracted from paraffin-embedded tissues of tumors from individual patients. Normal DNA was extracted from the surrounding normal tissue. Five microsatellite markers (BAT-25, BAT-26, D2S123, D5S346 and D17S250), recommended by a National Cancer Institute workshop on MSI, were used to analyze paired normal and tumor DNA.[@b20-jcp-19-056] Polymerase chain reaction (PCR) was performed using a DNA auto-sequencer (ABI 3730 genetic analyzer; Applied Biosystems, Foster City, CA). The shift of PCR products from tumor DNA was compared to that of DNA from normal mucosa. The size of each fluorescent PCR product was calculated using GeneMapper software (Applied Biosystems, Foster City, CA). According to the guideline of the National Cancer Institute, cases positive for ≥2 markers were considered as high-frequency MSI (MSI-H), while cases positive for \<2 markers as low-frequency MSI (MSI-L) or microsatellite stable (MSS).[@b20-jcp-19-056],[@b21-jcp-19-056]

7.. Follow-Up
-------------

The patients who underwent curative resection of GC were included in a follow-up program in the departments of Surgery at Seoul National University Bundang hospital.[@b22-jcp-19-056],[@b23-jcp-19-056] The follow-up investigations were scheduled at 3-month intervals for the first 2 years, then every 6 months for the next 3 years, and annually until the patient's death. The program consisted of physical examination, routine blood tests, endoscopy, and ultrasonography or computed tomography. Clinical outcomes were obtained from medical records until the date of death, loss-to-follow-up or October 2012 (end date of the study). Causes of death were ascertained by medical records and death certificate.

8.. Statistical Analysis
------------------------

To compare the clinicopathologic and molecular characteristics, Student's t-test or Chi-square test (Fisher's exact test) was used for continuous variables and categorical variables, respectively. The log-rank test was used in Kaplan-Meier survival analyses to investigate the effects of variables on survival. The effect of *H. pylori* infection on survival was assessed with the Cox proportional hazards regression, including all significant variables from the univariate analysis and age as covariates. All analyses were carried out using the SPSS for Windows (version 20.0; SPSS, Chicago, IL, USA). The results were considered statistically significant when p-values were less than 0.05.

RESULTS
=======

1.. Determination of the *H. pylori* Infection Status
-----------------------------------------------------

In the 849 GC patients, the *H. pylori* infection status was determined according to the strict definition, and these selection processes are summarized in [Fig. 1](#f1-jcp-19-056){ref-type="fig"}. We determined strict definition of *H. pylori* infection-negative as followed; 1) absent metaplastic atrophy both in the antrum and body, PG I/II ratio \>3; 2) non-applicable for atrophy either in the antrum or body but absent intestinal metaplasia both in the antrum and body, PG I/II ratio \>3; 3) absent atrophy both in the antrum and body, PG I/II ratio \>3 but present intestinal metaplasia either in the antrum or body; 4) present mild atrophy either in the antrum or body but absent intestinal metaplasia both in the antrum and body, PG I/II ratio \>3. By the three biopsy-based tests, 529 patients were diagnosed with current *H. pylori* infection, and 161 patients were diagnosed with previous infection by anti-*H. pylori* IgG positivity or eradication history. Altogether, 690 patients were categorized as HPIP-GC. In the 159 patients initially classified as HPIN-GC, patients with serologic and histologic diagnoses of severe gastric atrophy according to our definition, were excluded, because there is a high possibility of eliminating *H. pylori* infection during the process of gastric atrophy.[@b4-jcp-19-056],[@b7-jcp-19-056],[@b24-jcp-19-056] Finally, 36 patients were categorized as HPIN-GC.

2.. Clinicopathologic and Molecular Characteristics between *H. pylori*-Infection Positive and Negative Gastric Cancers
-----------------------------------------------------------------------------------------------------------------------

The clinicopathologic features between HPIP-GC and HPIN-GC were compared ([Table 1](#t1-jcp-19-056){ref-type="table"}). The clinical features such as age and sex were similar in both groups, except PG II and I/II ratio used for the diagnosis of HPIN-GC. Curative surgery was performed in 518 HPIP-GC and 24 HPIN-GC patients. Among 518 HPIP-GC patients who underwent curative surgery, nine patients were excluded from further analysis because of incomplete record or insufficient remaining tissue. In the pathologic analysis, there was no difference in tumor size between two groups, but HPIN-GC group showed a significantly higher frequency of cardia location than HPIP-GC (20.8% vs. 7.1%, P=0.013). The depth of invasion in HPIN-GC group was more advanced than that in HPIP-GC group, although there was no statistical significance (pT3-pT4, 37.5% for HPIN-GC vs. 28.5% for HPIP-GC, P=0.341). The proportion of lymph node metastasis in HPIN-GC group was more than that in HPIP-GC group, but there was no statistical significance (45.8% for HPIN-GC and 36.9% for HPIP-GC, P=0.378).

To investigate causative and prognostic factors in HPIN-GC, EBV in situ hybridization, p53 immunohistochemistry, and PCR-based MSI testing were performed in the surgical specimens ([Table 1](#t1-jcp-19-056){ref-type="table"}). Among 24 HPIN-GC who underwent curative surgery, one patient was excluded from further analysis because of insufficient remaining tissue. Age- and sex-matched 23 patients were randomly selected from HPIP-GC patients to properly compare with HPIN-GC patients ([Fig. 1](#f1-jcp-19-056){ref-type="fig"}). The positivity of EBV in both groups was low (6.7% vs. 7.7%), which was not significantly different. Similarly, the distributions of MSI-H and p53 positivity in HPIN-GC were not significantly different from those in HPIP-GC.

3.. Influence of *H. pylori* Status on Survival
-----------------------------------------------

In 509 HPIP-GC and 24 HPIN-GC patients, the influence of *H. pylori* status on long-term survival was evaluated. In the entire patients, 44 patients had died of tumor recurrence; the 5-year survival rate was 89.8% (standard error (SE), 1.5%). Only one of the HPIN-GC patients had died of tumor recurrence. Univariate analyses showed a significant association between relapse-free survival (RFS) and tumor size (≥3.5cm), Lauren classification, depth of invasion (pT1-pT2/pT3-pT4), and lymph node metastasis (pN0/pN1-pN3) (data not shown). With regard to overall survival (OS), there is an association with age, tumor size, Lauren classification, depth of invasion, and lymph node metastasis ([Fig. 2A--D](#f2-jcp-19-056){ref-type="fig"}). The 5-year survival rate were as follows; 99.1% (SE, 0.5%) in pT1-pT2 versus 70.9% (SE, 4.2%) in pT3-pT4, 99.4% (SE, 0.5%) in pN0 versus 86.6% (SE, 2.6%) in pN1-pN3, 96.5% (SE, 1.2%) in intestinal type versus 91.5% (SE, 1.8%) in diffused or mixed type, 98.6% (SE, 0.8%) in small tumor size (\<3.5cm) versus 83.6% (SE, 2.5%) in large size (≥3.5cm). In multivariate analyses, depth of invasion, lymph node metastasis, and Lauren classification were identified as independent prognostic factors for both RFS and OS ([Table 2](#t2-jcp-19-056){ref-type="table"}). However, the status of *H. pylori* infection was not a significant factor in both univariate and multivariate analyses ([Fig. 2E](#f2-jcp-19-056){ref-type="fig"}, [Table 2](#t2-jcp-19-056){ref-type="table"}). The 5-year rate of OS was 96.9% (SE, 0.8%) in *H. pylori*-positive and 93.8% (SE, 6.1%) in *H. pylori*-negative subjects, respectively. In addition, no significant effect of *H. pylori* status on survival was found in the subgroup analysis (such as tumor location, pT and pN stages) (data not shown).

4.. Molecular prognostic markers in *H. pylori*-Infection Negative Gastric Cancers
----------------------------------------------------------------------------------

For the evaluation of usefulness as a prognostic factor in HPIN-GC, the clinicopathologic features were stratified by MSI and p53 status ([Table 3](#t3-jcp-19-056){ref-type="table"}). In MSI-H, both HPIP-GC and HPIN-GC showed a tendency of older age, and intestinal classification, compared to MSI-L/MSS. HPIN-GC with MSI-L/MSS showed a significantly higher frequency of cardia location, compared to HPIP-GC with MSI-L/MSS (P=0.042), but the frequency of cardia location was still lower than that of noncardia location (21.1% vs. 78.9%). In p53 positive group, HPIN-GC had significantly higher frequencies of cardia location compared to HPIP-GC, but there was no statistical significance. The RFS and OS were assessed by MSI and p53 status in 23 HPIN-GC patients ([Fig. 2F](#f2-jcp-19-056){ref-type="fig"} and [2G](#f2-jcp-19-056){ref-type="fig"}), but there was no significant difference.

DISCUSSION
==========

During the past decade, the definition of HPIN-GC has been continuously changed in the literature.[@b3-jcp-19-056]--[@b7-jcp-19-056],[@b25-jcp-19-056] Kato et al. reported HPIN-GC prevalence of 2.0% to 10.6% using anti-*H. pylori* antibody and PG tests,[@b4-jcp-19-056] but the diagnostic tests have been challenged because of the spontaneous seroconversion of antibody and the false negative rate of PG tests.[@b26-jcp-19-056],[@b27-jcp-19-056] In other studies using serology and PCR test, the negative rates of *H. pylori* infection in GC were 14% and 18.8%.[@b5-jcp-19-056],[@b25-jcp-19-056] However, PCR test for *H. pylori* is not usually used in the clinical setting. The limited number (three or less) of diagnostic methods was considered as insufficient for detecting *H. pylori* infection, and more methods were needed to precisely diagnose the current and previous infection.[@b7-jcp-19-056] Matsuo et al. employed a combination of multiple methods such as serologic, endoscopic, and histologic evaluations to define *H. pylori* status as strictly as possible.[@b6-jcp-19-056] Regarding natural clearance or unexpected eradication of *H. pylori*, the absence of histologic gastritis and atrophic change was included in the definition of HPIN-GC. However, the definition of *H. pylori* status was extremely strict, in which even active gastritis in the absence of *H. pylori* detection was considered as previous *H. pylori* infection. Consequently, the prevalence of HPIN-GC was estimated 0.66%, which was much lower than those of the previous studies.[@b3-jcp-19-056]--[@b5-jcp-19-056],[@b8-jcp-19-056] The interobserver variability of histologic and endoscopic observation of atrophic change could be also problematic.[@b7-jcp-19-056] In our previous research, severe gastric atrophy was assessed by serum PG test and histologic evaluation of metaplastic gastric atrophy to exclude the GC patients with possible past infection, considering that *H. pylori* causes atrophy/intestinal metaplasia and can be eliminated after long-time colonization.[@b7-jcp-19-056],[@b24-jcp-19-056] The prevalence of HPIN-GC was calculated as 5.4%,[@b7-jcp-19-056] and the combination of multiple diagnostic methods was also employed in the present study.

The clinicopathologic features of the present study were compatible with the previous studies ([Table 1](#t1-jcp-19-056){ref-type="table"}).[@b3-jcp-19-056]--[@b7-jcp-19-056],[@b25-jcp-19-056] In the literature, the higher distributions of cardia location and diffuse type in HPIN-GC were frequently reported,[@b3-jcp-19-056],[@b5-jcp-19-056],[@b6-jcp-19-056],[@b25-jcp-19-056] and female predominance was also found.[@b3-jcp-19-056],[@b25-jcp-19-056] In the present study, the significantly higher frequency of cardia location was oserved ([Table 1](#t1-jcp-19-056){ref-type="table"}). With regard to the pathologic T and N staging, the advanced T and N stages in HPIN-GC were previously reported, but the results were not consistent.[@b3-jcp-19-056],[@b5-jcp-19-056],[@b28-jcp-19-056]

*H. pylori* infection as an independent prognostic factor in GC was recently demonstrated in the two studies conducted in Western countries.[@b3-jcp-19-056],[@b5-jcp-19-056] Meimarakis et al. reported that *H. pylori* infection was an independent prognostic factor for GC in addition to depth of invasion, lymph node metastasis, and age, defining *H. pylori* infection status by anti-*H. pylori* antibody, histologic analyses, and bacterial culture.[@b3-jcp-19-056] Thus, the author recommended careful follow-up and more aggressive treatment for HPIN-GC patients. In another study, in which *H. pylori* status was determined by serology and PCR for vacA, *H. pylori* infection, depth of invasion, lymph node metastasis, and tumor location were reported to be independent prognostic factors.[@b5-jcp-19-056] From the results of the two studies, the clinical implication of *H. pylori* infection was expanded to influence GC prognosis.

Similarly, in earlier research by our group,[@b7-jcp-19-056] the poor prognosis of HPIN-GC could be inferred from the clinicopathologic features of HPIN-GC such as advanced pT stage. However, the survival analysis of the present study revealed that there is no association between *H. pylori* status and GC prognosis ([Fig. 2E](#f2-jcp-19-056){ref-type="fig"} and [Table 2](#t2-jcp-19-056){ref-type="table"}). The pT and pN stages were identified as the most important prognostic factors for and RFS and OS ([Fig. 2A--B](#f2-jcp-19-056){ref-type="fig"} and [Table 2](#t2-jcp-19-056){ref-type="table"}). These findings are supported by the studies conducted in Taiwan and China, in which *H. pylori* status was not correlated with survival, although the definition of *H. pylori* infection was not strict in the studies.[@b8-jcp-19-056],[@b28-jcp-19-056] This discordance could be explained mainly by two factors. First, the two studies showing the prognostic value of *H. pylori* infection were conducted in Western GC patients,[@b3-jcp-19-056],[@b5-jcp-19-056] so the biologic and genetic aspects of *H. pylori* and GC could be different from those of Asian patients.[@b29-jcp-19-056] The better prognosis of GC in Asian countries could influence the prognostic results.[@b29-jcp-19-056]--[@b31-jcp-19-056] The good prognosis in Korean GC patients has been repeatedly reported previously.[@b31-jcp-19-056],[@b32-jcp-19-056] Second, in the Western studies,[@b3-jcp-19-056],[@b5-jcp-19-056] the definition of HPIN-GC was not strict as in Asian studies,[@b6-jcp-19-056],[@b7-jcp-19-056] and past infection, which can be ruled out by the presence of atrophic change, was overlooked, although IgG antibody test can detect a part of past infection. Long standing infection of *H. pylori* might lead to the clearance of *H. pylori* itself,[@b4-jcp-19-056],[@b7-jcp-19-056],[@b24-jcp-19-056] but the remaining atrophy and intestinal metaplasia still have a potential of carcinogenesis.

EBV-associated GC has distinct clinicopathologic characteristics, such as male predominance, young age, cardia location, and lymphoepithelial carcinoma.[@b33-jcp-19-056],[@b34-jcp-19-056] In contrast, EBV-associated GC was reported to not be associated with *H. pylori* infection, depth of invasion, lymph node metastasis, and the clinical stage in a meta-analysis.[@b33-jcp-19-056] Several studies demonstrated the differences in survival between EBV-positive and EBV-negative GC, but there has been still considerable controversy.[@b33-jcp-19-056] In the present study, the frequency of EBV positivity in both HPIP-GC and HPIN-GC was approximately 5%, and there was no association between EBV and HPIN-GC ([Table 1](#t1-jcp-19-056){ref-type="table"}). Given the limited number of EBV-positive patients, further analysis was not performed.

The frequency of MSI in GC has been reported from 9.5 to 44%,[@b9-jcp-19-056] and distinctive clinicopathologic features such as older age, distal location, larger size, intestinal classification, lower lymph node involvement, and improved survival have been suggested.[@b9-jcp-19-056],[@b12-jcp-19-056]--[@b14-jcp-19-056] The tendencies of older age and intestinal classification in MSI-H were also demonstrated in both HPIP-GC and HPIN-GC of the present study ([Table 3](#t3-jcp-19-056){ref-type="table"}). Regarding p53 expression in GC, the positivity rate has been reported to range from 4% to 71%, and the association with intestinal classification has been reported.[@b11-jcp-19-056],[@b15-jcp-19-056],[@b19-jcp-19-056] The prognostic value of p53 on survival is not conclusive, but several studies have demonstrated a poor prognosis.[@b15-jcp-19-056],[@b19-jcp-19-056] In the present study, the tendency of intestinal classification is observed in HPIP-GC (60.0% vs. 30.8%) and in HPIN-GC (54.5% vs. 33.3%) ([Table 3](#t3-jcp-19-056){ref-type="table"}). Interestingly, among all the 5 cardia cancer patients of HPIN-GC, four patients (80%) were p53 positive whereas only on patient was MSI-H, and the all the 5 cardia patients in HPIN-GC showed advanced pT (pT3-pT4, n=3) or pN (pN1-pN3, n=4) stages. The tendency of cardia location and advanced stage in p53 positive HPIN-GC patients could be due to the features of cardia cancer ([Table 3](#t3-jcp-19-056){ref-type="table"}). In GC patients with cardia location, the lack of association with *H. pylori* and the high expression of p53 were often noted in the previous studies.[@b35-jcp-19-056]--[@b37-jcp-19-056] With respect to prognosis, the interpretation of the clinicopathologic features according to MSI and p53 expression should be cautious, because the influence of MSI and p53 on survival was not clear in the present study ([Fig. 2F](#f2-jcp-19-056){ref-type="fig"}, [2G](#f2-jcp-19-056){ref-type="fig"}).

With the strict definition of *H. pylori* infection, we found 4.2% (36/849) cases of gastric cancer were HPIN-GC in the present study. The prevalence of HPIN-GC is regarded as low.[@b6-jcp-19-056],[@b7-jcp-19-056] In other words, recruiting an adequate sample size might take too long time. Thus, the attempt testing the molecular markers in HPIN-GC, like the present study, is needed for clinicians, although the number of cases was limited. To our knowledge, this is the first trial evaluating the prognostic molecular markers in HPIN-GC. The application of the prognostic markers, MSI and p53, to the patients with NPIN-GC should be deferred until the prognostic role of MSI and p53 becomes clear in HPIN-GC.

In conclusion, it was found that when applying the strict definition of *H. pylori* infection, the status of *H. pylori* infection was not a prognostic factor for survival in GC patients. Depth of invasion and lymph node metastasis were confirmed as the most important prognostic factors. The prognostic implication of MSI and p53 on survival in HPIN-GC patients was not clear.
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![Flow chart applying the strict definition of *H. pylori* infection for the comparison of clinicopathologic and molecular characteristics between *H. pylori*-infection positive and negative gastric cancer patients. ^a^Histology, rapid urease test, and culture for *H. pylori*. ^b^Patients who had undergone endoscopic resection or palliative surgery were excluded in the pathologic evaluation.](jcp-19-056f1){#f1-jcp-19-056}
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Effects of *H. pylori* status and molecular markers on overall survival. Overall survival in 533 gastric cancer patients according to (A) T stage, (B) N stage, (C) Lauren classification, (D) tumor size, and (E) *H. pylori* status. Overall survival in 24 *H. pylori*-infection negative gastric cancer patients according to (F) microsatellite instability (MSI) and (G) p53 expression.
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Clinicopathologic and molecular characteristics of gastric cancer patients by *H. pylori* infection status

  ------------------------------------------------------------------------ ----------------------------------------------------- ------------------------------------------------------ ---------
  Clinical analyses, total                                                 *H. pylori* positive                                  *H. pylori* negative                                   P-value
                                                                                                                                                                                        
  690                                                                      36                                                                                                           
                                                                                                                                                                                        
  M/F, n (%)                                                               464/226 (67.2/32.8)                                   24/12 (66.7/33.3)                                      0.942
  Age (mean±SD), years                                                     59.1±11.9                                             55.9±13.1                                              0.120
  Serum Pepsinogen (PG) test                                                                                                                                                            
    PG I (ng/mL)                                                           63.4±44.8                                             62.3±35.8                                              0.891
    PG II (ng/mL)                                                          25.0±7.4                                              11.4±7.1                                               \<0.001
    PG I/II ratio                                                          3.1±2.1                                               5.8±2.0                                                \<0.001
  Histologic Type[^\*^](#tfn1-jcp-19-056){ref-type="table-fn"}                                                                                                                          
    Tubular ADC, W/D, n (%)                                                156 (22.6)                                            7 (19.4)                                               0.961
    Tubular ADC, M/D, n (%)                                                222 (32.2)                                            11 (30.6)                                              
    Tubular ADC, P/D, n (%)                                                196 (28.4)                                            11 (30.6)                                              
    Signet ring cell carcinoma, n (%)                                      91 (13.2)                                             6 (6.2)                                                
    Others, n (%)[^†^](#tfn2-jcp-19-056){ref-type="table-fn"}              25 (3.6)                                              1 (2.8)                                                
  Treatment modalities                                                                                                                                                                  
    Endoscopic resection                                                   142 (20.6)                                            9 (25.0)                                               
    Curative surgery                                                       518 (75.1)                                            23 (63.9)                                              0.120
    Palliative surgery                                                     30 (4.3)                                              4 (11.1)                                               
                                                                                                                                                                                        
  Pathologic analyses, total[^‡^](#tfn3-jcp-19-056){ref-type="table-fn"}   *H. pylori* positive                                  *H. pylori* negative                                   P-value
                                                                                                                                                                                        
  509                                                                      24                                                                                                           
                                                                                                                                                                                        
  Tumor size (mean±SD), cm                                                 4.1±2.7                                               3.9±1.8                                                0.877
  Tumor location                                                                                                                                                                        
    Cardia, n (%)[^§^](#tfn4-jcp-19-056){ref-type="table-fn"}              36 (7.1)                                              5 (20.8)                                               0.013
    Noncardia, n (%)                                                       473 (92.9)                                            19 (79.2)                                              
  Lauren classification                                                                                                                                                                 
    Intestinal, n (%)                                                      253 (49.7)                                            10 (41.7)                                              0.441
    Diffuse or mixed, n (%)                                                256 (50.3)                                            14 (58.3)                                              
  Depth of invasion, n (%)                                                                                                                                                              
    pT1--pT2                                                               364 (71.5)                                            15 (62.5)                                              0.341
    pT3--pT4                                                               145 (28.5)                                            9 (37.5)                                               
  Lymph node metastasis, n (%)                                                                                                                                                          
    pN0                                                                    321 (63.1)                                            13 (54.2)                                              0.378
    pN1--pN3                                                               188 (36.9)                                            11 (45.8)                                              
  TNM stage, n (%)                                                                                                                                                                      
    I                                                                      309 (60.7)                                            11 (45.8)                                              0.146
    II, III, IV                                                            200 (39.9)                                            13 (54.2)                                              
                                                                                                                                                                                        
  Molecular analyses, total                                                *H. pylori* positive                                  *H. pylori* negative                                   P-value
                                                                                                                                                                                        
  23[^∥^](#tfn5-jcp-19-056){ref-type="table-fn"}                           23                                                                                                           
                                                                                                                                                                                        
  EBV, n (%)                                                                                                                                                                            
    Positive                                                               1 (7.7)[^¶^](#tfn6-jcp-19-056){ref-type="table-fn"}   1 (6.7)[^¶^](#tfn6-jcp-19-056){ref-type="table-fn"}    1.000
    Negative                                                               12 (92.3)                                             14 (93.3)                                              
  MSI, n (%)                                                                                                                                                                            
    MSI-High                                                               2 (8.7)                                               3 (13.6)[^¶^](#tfn6-jcp-19-056){ref-type="table-fn"}   0.665
    MSI-Low/MSS[^\#^](#tfn7-jcp-19-056){ref-type="table-fn"}               21 (91.3)                                             19 (86.4)                                              
  p53, n (%)                                                                                                                                                                            
    Positive                                                               10 (43.5)                                             11 (47.8)                                              0.767
    Negative                                                               13 (56.5)                                             12 (52.2)                                              
  ------------------------------------------------------------------------ ----------------------------------------------------- ------------------------------------------------------ ---------

ADC, adenocarcinoma; W/D, well-differentiated; M/D, moderately differentiated; P/D, poorly differentiated.

Includes mucinous adenocarcinoma, adenosquamous carcinoma, and undifferentiated carcinoma.

Patients who underwent endoscopic resection or palliative surgery were excluded in the pathologic analysis. Patients with insufficient tissue or incomplete record were also excluded.

Located within 2 cm below the gastroesophageal junction.

Age- and sex-matched patients randomly selected from *H. pylori*-infection positive gastric cancer patients.

EBV or MSI were not performed due to insufficient remaining tissue.

Microsatellite instability-low or microsatellite stable.

###### 

Prognostic factors for relapse-free survival and overall survival in multivariate Cox proportional hazard analysis

                                                                      Relapse-free survival   Overall survival                        
  ------------------------------------------------------------------- ----------------------- ------------------ -------------------- ---------
  Depth of invasion[^†^](#tfn8-jcp-19-056){ref-type="table-fn"}       6.58 (2.92--14.81)      \<0.001            5.30 (2.20--12.74)   \<0.001
  Lymph node metastasis[^‡^](#tfn9-jcp-19-056){ref-type="table-fn"}   6.67 (2.47--18.04)      \<0.001            6.70 (2.20--20.44)   0.001
  Lauren classification                                               1.96 (1.06--3.64)       0.033              2.24 (1.10--4.53)    0.026
  Age (years)                                                         1.02 (1.00--1.04)       0.063              1.03 (1.01--1.06)    0.007
  *H. pylori* infection status                                        0.780 (0.19--3.21)      0.731              0.51 (0.07--3.70)    0.504

pT1-pT2 vs. pT3-pT4,

pN0 vs. pN1-pN3.

###### 

Clinicopathologic characteristics of *H. pylori*-infection positive and negative gastric cancer patients by MSI and p53 status

  --------------------------------------------------------------- ----------------------------- ----------------------------- ----------------------------- ----------- ----------- ----------- ------ ---------------------------------------------------
                                                                  MSI-High                      MSI-Low/MSS                                                                                            
  *H. pylori* positive (n=2)                                      *H. pylori* negative (n=3)    *H. pylori* positive (n=21)   *H. pylori* negative (n=19)                                              
                                                                                                                                                                                                       
  n                                                               \%                            n                             \%                            n           \%          n           \%     
                                                                                                                                                                                                       
  M/F, n (%)                                                      1/1                           50/50                         2/1                           66.7/33.3   13/8        61.9/38.1   11/8   57.9/42.1
  Age (mean±SD), years                                            65.0±11.3                                                   64.7±8.0                      53.6±11.5   53.4±12.0                      
  Size (mean±SD), cm                                                                            2.0±0.0                                                     3.6±1.5                 3.6±2.3            3.9±1.8
  Location                                                                                                                                                                                             
    Cardia, n (%)[^\*^](#tfn10-jcp-19-056){ref-type="table-fn"}   0                             0                             1                             33.3        0           0           4      21.1[^†^](#tfn11-jcp-19-056){ref-type="table-fn"}
    Noncardia, n (%)                                              2                             100                           2                             66.7        21          100         15     78.9
  Lauren classification                                                                                                                                                                                
    Intestinal, n (%)                                             2                             100                           3                             100.0       8           38.1        6      31.6
    Diffuse or mixed, n (%)                                       0                             0                             0                             0.0         13          61.9        13     68.4
  Depth of invasion, n (%)                                                                                                                                                                             
    pT1--pT2                                                      2                             100                           1                             33.3        14          66.7        13     68.4
    pT3--pT4                                                      0                             0                             2                             66.7        7           33.3        6      31.6
  Lymph node metastasis, n (%)                                                                                                                                                                         
    pN0                                                           2                             100                           2                             66.7        14          66.7        10     52.6
    pN1--pN3                                                      0                             0                             1                             33.3        7           33.3        9      47.4
                                                                                                                                                                                                       
                                                                  p53 positive                  p53 negative                                                                                           
                                                                                                                                                                                                       
  *H. pylori* positive (n=10)                                     *H. pylori* negative (n=11)   *H. pylori* positive (n=13)   *H. pylori* negative (n=12)                                              
                                                                                                                                                                                                       
  n                                                               \%                            n                             \%                            n           \%          n           \%     
                                                                                                                                                                                                       
  M/F, n (%)                                                      7/3                           70.0/30.0                     7/4                           63.6/36.4   7/6         53.8/46.2   7/5    58.3/41.7
  Age (mean±SD), years                                            57.2±10.9                     55.5±12.5                     52.5±12.3                     53.4±12.3                                  
  Size (mean±SD), cm                                              4.2±2.5                       3.8±2.2                       3.0±1.9                       4.0±1.7                                    
  Location                                                                                                                                                                                             
    Cardia, n (%)[^\*^](#tfn10-jcp-19-056){ref-type="table-fn"}   0                             0                             4                             36.4        0           0           1      8.3
    Noncardia, n (%)                                              10                            100                           7                             63.6        13          100         11     91.7
  Lauren classification                                                                                                                                                                                
    Intestinal, n (%)                                             6                             60.0                          6                             54.5        4           30.8        4      33.3
    Diffuse or mixed, n (%)                                       4                             40.0                          5                             45.5        9           69.2        8      66.7
  Depth of invasion, n (%)                                                                                                                                                                             
    pT1--pT2                                                      8                             80.0                          8                             72.7        8           61.5        7      58.3
    pT3--pT4                                                      2                             20.0                          3                             27.3        5           38.5        5      41.7
  Lymph node metastasis, n (%)                                                                                                                                                                         
    pN0                                                           7                             70.0                          6                             54.5        9           69.2        6      50.0
    pN1-pN3                                                       3                             30.0                          5                             45.5        4           30.8        6      50.0
  --------------------------------------------------------------- ----------------------------- ----------------------------- ----------------------------- ----------- ----------- ----------- ------ ---------------------------------------------------

Located within 2 cm below the gastroesophageal junction.

P=0.042, compared to *H. pylori* infection-positive gastric cancer with MSI-Low/MSS.

[^1]: The first two authors equally contributed to this work.
